Where's the value in Pfizer's $17bn Hospira buy?

With Pfizer's pending $17bn acquisition of Hospira there's a lot of interest in the target company's biosimilar portfolio, given the potential for cheaper copies of biological medicines to steal substantial market share from major drug makers, but the most valuable part of the deal for Pfizer could be the addition of Hospira's generic injectable products and manufacturing capabilities.